Heteroaryl derivatives of suvorexant as OX1R selective PET ligand candidates: Cu-mediated 18F-fluorination of boroxines, in vitro and initial in vivo evaluation.

IF 3.1 3区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Kim-Viktoria Bolik, Jan Hellmann, Simone Maschauer, Eduard Neu, Jürgen Einsiedel, Patrick Riss, Nora Vogg, Jörg König, Martin F Fromm, Harald Hübner, Peter Gmeiner, Olaf Prante
{"title":"Heteroaryl derivatives of suvorexant as OX1R selective PET ligand candidates: Cu-mediated <sup>18</sup>F-fluorination of boroxines, in vitro and initial in vivo evaluation.","authors":"Kim-Viktoria Bolik, Jan Hellmann, Simone Maschauer, Eduard Neu, Jürgen Einsiedel, Patrick Riss, Nora Vogg, Jörg König, Martin F Fromm, Harald Hübner, Peter Gmeiner, Olaf Prante","doi":"10.1186/s13550-024-01141-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The orexin receptor (OXR) plays a role in drug addiction and is aberrantly expressed in colorectal tumors. Subtype-selective OXR PET ligands suitable for in vivo use have not yet been reported. This work reports the development of <sup>18</sup>F-labeled OXR PET ligand candidates derived from the OXR antagonist suvorexant and the OX1R-selective antagonist JH112.</p><p><strong>Results: </strong>Computational analysis predicted that fluorine substitution (1e) and introduction of the fluorobenzothiazole scaffold (1f) would be suitable for maintaining high OX1R affinity. After multi-step synthesis of 1a-1f, in vitro OXR binding studies confirmed the molecular dynamics calculations and revealed single-digit nanomolar OX1R affinities for 1a-f, ranging from 0.69 to 2.5 nM. The benzothiazole 1f showed high OX1R affinity (K<sub>i</sub> = 0.69 nM), along with 77-fold subtype selectivity over OX2R. Cu-mediated <sup>18</sup>F-fluorination of boroxine precursors allowed for a shortened reaction time of 5 min to provide the non-selective OXR ligand [<sup>18</sup>F]1c and its selective OX1R congener [<sup>18</sup>F]1f in activity yields of 14% and 22%, respectively, within a total synthesis time of 52-76 min. [<sup>18</sup>F]1c and [<sup>18</sup>F]1f were stable in plasma and serum in vitro, with logD<sub>7.4</sub> of 2.28 ([<sup>18</sup>F]1c) and 2.37 ([<sup>18</sup>F]1f), and high plasma protein binding of 66% and 77%, respectively. Dynamic PET imaging in rats showed similar brain uptake of [<sup>18</sup>F]1c (0.17%ID/g) and [<sup>18</sup>F]1f (0.15%ID/g). However, preinjection of suvorexant did not significantly block [<sup>18</sup>F]1c or [<sup>18</sup>F]1f uptake in the rat brain. Pretreatment with cyclosporine A to study the role of P-glycoprotein (P-gp) in limiting brain accumulation moderately increased brain uptake of [<sup>18</sup>F]1c and [<sup>18</sup>F]1f. Accordingly, in vitro experiments demonstrated that the P-gp inhibitor zosuquidar only moderately inhibited polarized, basal to apical transport of 1c (p < 0.05) and had no effect on the transport of 1f, indicating that P-gp does not play a relevant role in brain accumulation of [<sup>18</sup>F]1c and [<sup>18</sup>F]1f in vivo.</p><p><strong>Conclusions: </strong>The in vitro and in vivo results of [<sup>18</sup>F]1c and [<sup>18</sup>F]1f provide a solid basis for further development of suitable OXR PET ligands for brain imaging.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"80"},"PeriodicalIF":3.1000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374953/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-024-01141-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The orexin receptor (OXR) plays a role in drug addiction and is aberrantly expressed in colorectal tumors. Subtype-selective OXR PET ligands suitable for in vivo use have not yet been reported. This work reports the development of 18F-labeled OXR PET ligand candidates derived from the OXR antagonist suvorexant and the OX1R-selective antagonist JH112.

Results: Computational analysis predicted that fluorine substitution (1e) and introduction of the fluorobenzothiazole scaffold (1f) would be suitable for maintaining high OX1R affinity. After multi-step synthesis of 1a-1f, in vitro OXR binding studies confirmed the molecular dynamics calculations and revealed single-digit nanomolar OX1R affinities for 1a-f, ranging from 0.69 to 2.5 nM. The benzothiazole 1f showed high OX1R affinity (Ki = 0.69 nM), along with 77-fold subtype selectivity over OX2R. Cu-mediated 18F-fluorination of boroxine precursors allowed for a shortened reaction time of 5 min to provide the non-selective OXR ligand [18F]1c and its selective OX1R congener [18F]1f in activity yields of 14% and 22%, respectively, within a total synthesis time of 52-76 min. [18F]1c and [18F]1f were stable in plasma and serum in vitro, with logD7.4 of 2.28 ([18F]1c) and 2.37 ([18F]1f), and high plasma protein binding of 66% and 77%, respectively. Dynamic PET imaging in rats showed similar brain uptake of [18F]1c (0.17%ID/g) and [18F]1f (0.15%ID/g). However, preinjection of suvorexant did not significantly block [18F]1c or [18F]1f uptake in the rat brain. Pretreatment with cyclosporine A to study the role of P-glycoprotein (P-gp) in limiting brain accumulation moderately increased brain uptake of [18F]1c and [18F]1f. Accordingly, in vitro experiments demonstrated that the P-gp inhibitor zosuquidar only moderately inhibited polarized, basal to apical transport of 1c (p < 0.05) and had no effect on the transport of 1f, indicating that P-gp does not play a relevant role in brain accumulation of [18F]1c and [18F]1f in vivo.

Conclusions: The in vitro and in vivo results of [18F]1c and [18F]1f provide a solid basis for further development of suitable OXR PET ligands for brain imaging.

作为 OX1R 选择性 PET 配体候选化合物的苏沃先的杂芳基衍生物:铜介导的硼氧烷 18F 氟化、体外和初步体内评估。
背景:奥曲肽受体(OXR)在药物成瘾中发挥作用,并在结直肠肿瘤中异常表达。适合体内使用的亚型选择性 OXR PET 配体尚未见报道。本研究报告了从 OXR 拮抗剂 suvorexant 和 OX1R 选择性拮抗剂 JH112 衍生出的 18F 标记 OXR PET 配体候选化合物的开发情况:计算分析预测,氟取代(1e)和引入氟苯并噻唑支架(1f)适合于保持高 OX1R 亲和力。经过多步合成 1a-1f,体外 OXR 结合研究证实了分子动力学计算结果,并发现 1a-f 的 OX1R 亲和力为个位数纳摩尔,从 0.69 到 2.5 nM 不等。苯并噻唑 1f 显示出很高的 OX1R 亲和力(Ki = 0.69 nM),对 OX2R 的亚型选择性高达 77 倍。铜介导的硼氧前体 18F 氟化反应时间缩短了 5 分钟,在总合成时间为 52-76 分钟的情况下,提供了非选择性 OXR 配体 [18F]1c 及其选择性 OX1R 同系物 [18F]1f,活性产率分别为 14% 和 22%。[18F]1c和[18F]1f在体外血浆和血清中稳定,logD7.4分别为2.28([18F]1c)和2.37([18F]1f),血浆蛋白结合率分别为66%和77%。大鼠动态 PET 成像显示,[18F]1c(0.17%ID/g)和[18F]1f(0.15%ID/g)的脑摄取量相似。然而,预先注射舒伐沙坦并不能明显阻止大鼠大脑对[18F]1c或[18F]1f的摄取。为研究 P 糖蛋白(P-gp)在限制脑内蓄积方面的作用,用环孢素 A 预处理可适度增加大脑对 [18F]1c 和 [18F]1f 的摄取。相应地,体外实验表明,P-gp 抑制剂 zosuquidar 只适度抑制体内 1c (p 18F]1c 和 [18F]1f )的极化、基底到顶端转运:[18F]1c和[18F]1f的体外和体内研究结果为进一步开发用于脑成像的合适OXR PET配体奠定了坚实的基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
EJNMMI Research
EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-
CiteScore
5.90
自引率
3.10%
发文量
72
审稿时长
13 weeks
期刊介绍: EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信